The Institute for Clinical and Economic Review (ICER) is targeting unjustified price increases (UPIs) as it looks to expand its focus beyond quality-adjust life year (QALY) analysis, Pharmaceutical Executive reports.
The nonprofit recently released a draft protocol for a new annual report that will spotlight drug price increases, namely those it determines to be unjustified.
“The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified,” ICER states in its draft protocol.
In its report, ICER included a timeline for the deployment of UPI reports. The first report is planned for Oct. 8.
” … ICER proposed to generate an annual report of up to 13 drugs that have experienced substantial price increases over a two-year time period,” ICER states. “ICER will review changes in the evidence based for these drugs, and report on whether potential evidentiary support for price increases was found.”
To read more on Pharmaceutical Executive, click here.
Click here to read ICER’s full draft protocol for the new reports.
